Table S1 contains two items that require correction. The OMV vaccine given subcutaneously is listed as providing 0% protection against challenge; in fact, it provided 60% protection. Additionally, the challenge information should indicate 1000 CFU by aerosol instead of 5000 CFU intranasally. Please view the correct Table S1 here:
Citation: Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GCKW, White LJ, et al. (2013) Correction: Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes. PLoS Negl Trop Dis 7(2): 10.1371/annotation/20664ec9-17e4-4ba6-8c65-481a70a5c4ad. doi:10.1371/annotation/20664ec9-17e4-4ba6-8c65-481a70a5c4ad
Published: February 26, 2013
Copyright: © 2013 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.